GlassScriptPhysician profile
Mark R Edelstein
NPI 1750385696
$6,149.65
in general payments reported to CMS, 2019-2025
28 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $789 · 2021: $1,625 · 2022: $459 · 2023: $505 · 2024: $632 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $985.81 | 2021-2025 | Optimizer |
| Boston Scientific Corporation | $602.68 | 2020-2024 | Embold Fibered, Therasphere Administration Set, Watchman |
| Inari Medical, INC. | $557.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $549.05 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $547.99 | 2019-2025 | |
| Amgen INC. | $413.18 | 2019-2024 | Repatha |
| Pfizer INC. | $327.92 | 2019-2024 | |
| Heartflow, INC. | $326.54 | 2019-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $190.77 | 2019-2021 | |
| Penumbra, INC. | $174.35 | 2023-2025 | Indigo System |
| Amarin Pharma, INC. | $165.80 | 2019-2021 | |
| Medtronic Vascular, INC. | $164.73 | 2019-2020 | |
| Silk Road Medical, INC. | $153.81 | 2021 | |
| Stryker Corporation | $150.29 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Terumo Medical Corporation | $115.10 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $100.00 | 2021 | |
| Abbott Laboratories | $87.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $78.53 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $78.08 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.46 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.97 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $67.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $51.26 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.91 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $27.12 | 2019-2021 | |
| Akcea Therapeutics, INC. | $24.43 | 2019 | |
| Merck Sharp & Dohme LLC | $18.75 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Edelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.